Seattle Genetics, Inc. (SGEN): Price and Financial Metrics


Seattle Genetics, Inc. (SGEN): $133.47

-5.87 (-4.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SGEN POWR Grades


  • Value is the dimension where SGEN ranks best; there it ranks ahead of 72.4% of US stocks.
  • SGEN's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • SGEN ranks lowest in Momentum; there it ranks in the 4th percentile.

SGEN Stock Summary

  • The ratio of debt to operating expenses for Seagen Inc is higher than it is for about merely 7.87% of US stocks.
  • SGEN's price/sales ratio is 16.7; that's higher than the P/S ratio of 91.52% of US stocks.
  • As for revenue growth, note that SGEN's revenue has grown -27.63% over the past 12 months; that beats the revenue growth of only 5.93% of US companies in our set.
  • Stocks that are quantitatively similar to SGEN, based on their financial statements, market capitalization, and price volatility, are INCY, QRVO, BGNE, UMC, and WDC.
  • SGEN's SEC filings can be seen here. And to visit Seagen Inc's official web site, go to www.seattlegenetics.com.

SGEN Valuation Summary

  • SGEN's price/earnings ratio is 51.1; this is 40% higher than that of the median Healthcare stock.
  • Over the past 243 months, SGEN's price/sales ratio has gone down 1289.2.
  • SGEN's price/earnings ratio has moved up 66.6 over the prior 243 months.

Below are key valuation metrics over time for SGEN.

Stock Date P/S P/B P/E EV/EBIT
SGEN 2021-08-31 12.8 9.0 51.1 50.3
SGEN 2021-08-30 12.9 9.0 51.4 50.6
SGEN 2021-08-27 12.7 8.9 50.8 50.1
SGEN 2021-08-26 12.9 9.1 51.5 50.7
SGEN 2021-08-25 13.0 9.1 51.7 51.0
SGEN 2021-08-24 12.8 9.0 51.2 50.4

SGEN Growth Metrics

    The 4 year price growth rate now stands at 286.78%.
  • Its year over year net cashflow from operations growth rate is now at 555.83%.
  • The 2 year net income to common stockholders growth rate now stands at -76.99%.
Over the past 34 months, SGEN's revenue has gone up $865,062,000.

The table below shows SGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,574.371 -499.007 -674.471
2021-09-30 1,745.814 -26.48 -332.748
2021-06-30 2,383.485 814.141 597.266
2021-03-31 2,273.005 800.301 660.652
2020-12-31 2,175.536 856.568 613.67
2020-09-30 1,864.047 655.573 472.405

SGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SGEN has a Quality Grade of C, ranking ahead of 74.02% of graded US stocks.
  • SGEN's asset turnover comes in at 0.44 -- ranking 102nd of 681 Pharmaceutical Products stocks.
  • BPMC, OCGN, and OTLC are the stocks whose asset turnover ratios are most correlated with SGEN.

The table below shows SGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.440 0.836 -0.133
2021-06-30 0.640 0.882 0.271
2021-03-31 0.693 0.889 0.354
2020-12-31 0.773 0.900 0.398
2020-09-30 0.788 0.910 0.374
2020-06-30 0.475 0.901 -0.184

SGEN Price Target

For more insight on analysts targets of SGEN, see our SGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $188.25 Average Broker Recommendation 1.58 (Moderate Buy)

SGEN Stock Price Chart Interactive Chart >

Price chart for SGEN

SGEN Price/Volume Stats

Current price $133.47 52-week high $192.79
Prev. close $139.34 52-week low $105.43
Day low $132.09 Volume 1,069,100
Day high $138.74 Avg. volume 1,130,308
50-day MA $138.97 Dividend yield N/A
200-day MA $150.63 Market Cap 24.57B

Seattle Genetics, Inc. (SGEN) Company Bio


Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company was founded in 1998 and is based in Bothell, Washington.


SGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

SGEN Latest Social Stream


Loading social stream, please wait...

View Full SGEN Social Stream

Latest SGEN News From Around the Web

Below are the latest news stories about Seagen Inc that investors may wish to consider to help them evaluate SGEN as an investment opportunity.

Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

BOTHELL, Wash., & COPENHAGEN, Denmark, February 24, 2022--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated

Yahoo | February 24, 2022

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

COPENHAGEN, Denmark & BOTHELL, Wash., February 24, 2022--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a

Yahoo | February 24, 2022

Downgrade: Here's How Analysts See Seagen Inc. (NASDAQ:SGEN) Performing In The Near Term

One thing we could say about the analysts on Seagen Inc. ( NASDAQ:SGEN ) - they aren't optimistic, having just made a...

Yahoo | February 16, 2022

Berenberg Bank Thinks Seagen’s Stock is Going to Recover

In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Seagen (SGEN – Research Report), with a price target of $180.00. The company's shares closed last Monday at $124.51, close to its 52-week low of $118.00. According to TipRanks.com, Shu has 0 stars on 0-5 stars ranking scale with an average return of -25.1% and a 14.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Sensei Biotherapeutics, and Sarepta Therapeutics. Seagen has an analyst consensus of Moderate Buy, with a price target consensus of $161.14, which is a 29.2% upside from current levels.

Catie Powers on TipRanks | February 15, 2022

Leerink Partners Thinks Seagen’s Stock is Going to Recover

Leerink Partners analyst Andrew Berens maintained a Buy rating on Seagen (SGEN – Research Report) today. The company's shares closed last Tuesday at $128.17, close to its 52-week low of $118.00. According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.9% and a 42.2% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals. Currently, the analyst consensus on Seagen is a Moderate Buy with an average price target of $161.62, implying a 29.8% upside from current levels. In a report issued on February 10, J.P.

Brian Anderson on TipRanks | February 15, 2022

Read More 'SGEN' Stories Here

SGEN Price Returns

1-mo -3.28%
3-mo 11.59%
6-mo N/A
1-year -13.15%
3-year 93.04%
5-year 102.17%
YTD -13.67%
2021 -11.73%
2020 53.28%
2019 101.66%
2018 5.91%
2017 1.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9501 seconds.